Background: Classically, vitamin D has been implicated in bone health by promoting calcium absorption in the gut and maintenance of serum calcium and phosphate concentrations, as well as by its action on bone growth and reorganization through the action of osteoblasts and osteoclasts cells. However, in the last 2 decades, novel actions of vitamin D have been discovered. The present report summarizes both classic and novel actions of vitamin D. Summary: 1,25(OH)2 vitamin D, the active metabolite of vitamin D, also known as calcitriol, regulates not only calcium and phosphate homeostasis but also cell proliferation and differentiation, and has a key a role to play in the responses of the immune and nervous systems. Current effects of vitamin D include xenobiotic detoxification, oxidative stress reduction, neuroprotective functions, antimicrobial defense, immunoregulation, anti-inflammatory/anticancer actions, and cardiovascular benefits. The mechanism of action of calcitriol is mediated by the vitamin D receptor, a subfamily of nuclear receptors that act as transcription factors into the target cells after forming a heterodimer with the retinoid X receptor. This kind of receptors has been found in virtually all cell types, which may explain its multiple actions on different tissues. Key Messages: In addition to classic actions related to mineral homeostasis, vitamin D has novel actions in cell proliferation and differentiation, regulation of the innate and adaptative immune systems, preventive effects on cardiovascular and neurodegenerative diseases, and even antiaging effects.

Keywords:
Vitamin D, Calcitriol, Calcium, Novel actions
1.
Valero-Zanuya M, Hawkins-Carranza F: Metabolism, endogenous and exogenous sources of vitamin D. Rev Esp Enferm Metab Oseas 2007; 16: 63–70.
2.
Silva MC, Furlanetto TW: Intestinal absorption of vitamin D: a systematic review. Nutr Rev 2018; 76: 60–76
3.
Mulligan GB, Licata A: Taking vitamin D with the largest meal improves absorption and results in higher serum levels of 25-hydroxyvitamin D. J Bone Miner Res 2010; 25: 928–930.
4.
Compston JE, Merrett AL, Hammett FG, Magill P: Comparison of the appearance of radiolabelled vitamin D3 and 25-hydroxy-vitamin D3 in the chylomicron fraction of plasma after oral administration in man. Clin Sci (Lond) 1981; 60: 241–243.
5.
Cisneros C, Thompson T, Baluyot N, Smith AC, Tapavicza E: The role of tachysterol in vitamin D photosynthesis – a non-adiabatic molecular dynamics study. Phys Chem Chem Phys 2017; 19: 5763–5777.
6.
Jones G: Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008; 88: 582S–586S.
7.
Tanaka Y, Wichmann JK, De Luca HF, Kobayashi Y, Ikekawa N: Metabolism and binding properties of 24,24-difluoro-25-hydroxyvitamin D3. Arch Biochem Biophys 1983; 225: 649–655.
8.
Norman AW: Sunlight, season, skin pigmentation, vitamin D, and 25-hydroxyvitamin D: Integral components of the vitamin D endocrine system. Am J Clin Nutr 1998; 67: 1108–1110.
9.
Savastano S, Barrea L, Savanelli MC, Nappi F, Di Somma C, Orio F, Colao A: Low vitamin D status and obesity: role of nutritionist. Rev Endocr Metab Disord 2017; 18: 215–225.
10.
Willnow TE, Nykjaer A: Pathways for kidney-specific uptake of the steroid hormone 25-hydroxyvitamin D3. Curr Opin Lipidol 2002; 13: 255–260.
11.
Christakos S: In search of regulatory circuits that control the biological activity of vitamin D. J Biol Chem 2017; 292: 17559–17560.
12.
Nishimura A, Shinki T, Jin CH, Ohyama Y, Noshiro M, Okuda K, Suda T: Regulation of messenger ribonucleic acid expression of 1 alpha,25-dihydroxyvitamin D3-24-hydroxylase in rat osteoblasts. Endocrinology 1994; 134: 1794–1799.
13.
Brown RB, Razzaque MS: Dysregulation of phosphate metabolism and conditions associated with phosphate toxicity. Bonekey Rep 2015; 4: 705.
14.
Perwad F, Portale AA: Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblast growth factor 23. Mol Cell Endocrinol 2011; 347: 17–24.
15.
Clinckspoor I, Verlinden L, Mathieu C, Bouillon R, Verstuyf A, Decallonne B: Vitamin D in thyroid tumorigenesis and development. Prog Histochem Cytochem 2013; 48: 65–98.
16.
Naveh-Many T, Marx R, Keshet E, Pike JW, Silver J: Regulation of 1,25-dihydroxyvitamin D3 receptor gene expression by 1,25-dihydroxyvitamin D3 in the parathyroid in vivo. J Clin Invest 1990; 86: 1968–1975.
17.
Wongdee K, Charoenphandhu N: Vitamin D-enhanced duodenal calcium transport. Vitam Horm 2015; 98: 407–440.
18.
Glendenning P, Ratajczak T, Dick IM, Prince RL: Calcitriol upregulates expression and activity of the 1b isoform of the plasma membrane calcium pump in immortalized distal kidney tubular cells. Arch Biochem Biophys 2000; 380: 126–132.
19.
Kuchuk NO, van Schoor NM, Pluijm SM, Chines A, Lips P: Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective. J Bone Miner Res 2009; 24: 693–701.
20.
Harada S, Mizoguchi T, Kobayashi Y, Nakamichi Y, Takeda S, Sakai S, Takahashi F, Saito H, Yasuda H, Udagawa N, Suda T, Takahashi N: Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J Bone Miner Res 2012; 27: 461–73.
21.
Murali SK, Roschger P, Zeitz U, Klaushofer K, Andrukhova O, Erben RG: FGF23 Regulates bone mineralization in a 1,25(OH)2 D3 and klotho-independent manner. J Bone Miner Res 2016; 31: 129–142.
22.
Nakamichi Y, Udagawa N, Suda T, Takahashi N: Mechanisms involved in bone resorption regulated by vitamin D. J Steroid Biochem Mol Biol 2017;pii:S0960-0760(17)30334-5..
23.
Courbebaisse M, Lanske B: Biology of fibroblast growth factor 23: from physiology to pathology. Cold Spring Harb Perspect Med 2017;pii:a031260.
24.
Feldman D, Krishnan A, Swami S: Vitamin D: biology, actions, and clinical implications; in Marcus R, Feldman D, Dempster D, Luckey M, Cauley J (eds): Osteoporosis, ed 4. Waltham, Academic Press, 2013, pp 283–328.
25.
Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, Lieben L, Mathieu C, Demay M: Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29: 726–776.
26.
DeLuca HF: Evolution of our understanding of vitamin D. Nutr Rev 2008; 66(10 suppl 2):S73–S87.
27.
Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G: Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev 2016; 96: 365–408.
28.
Pike JW, Meyer MB, Benkusky NA, Lee SM, St John H, Carlson A, Onal M, Shamsuzzaman S: Genomic determinants of vitamin D-regulated gene expression. Vitam Horm 2016; 100: 21–45.
29.
Yin JW, Wang G: The mediator complex: a master coordinator of transcription and cell lineage development. Development 2014; 141: 977–987.
30.
Dhawan P, Peng X, Sutton AL, MacDonald PN, Croniger CM, Trautwein C, Centrella M, McCarthy TL, Christakos S: Functional cooperation between CCAAT/enhancer-binding proteins and the vitamin D receptor in regulation of 25-hydroxyvitamin D3 24-hydroxylase. Mol Cell Biol 2005; 25: 472–487.
31.
Meyer MB, Benkusky NA, Pike JW: Selective distal enhancer control of the Mmp13 gene identified through clustered regularly interspaced short palindromic repeat (CRISPR) genomic deletions. J Biol Chem 2015; 290: 11093–11107.
32.
Seth-Vollenweider T, Joshi S, Dhawan P, Sif S, Christakos S: Novel mechanism of negative regulation of 1,25-dihydroxyvitamin D3-induced 25-hydroxyvitamin D3 24-hydroxylase (Cyp24a1) transcription: epigenetic modification involving cross-talk between protein-arginine methyltransferase 5 and the SWI/SNF complex. J Biol Chem 2014; 289: 33958–33970.
33.
Haussler MR, Whitfield GK, Haussler CA, Sabir MS, Khan Z, Sandoval R, Jurutka PW: 1,25-Dihydroxyvitamin D and Klotho: a tale of two renal hormones coming of age. Vitam Horm 2016; 100: 165–230.
34.
De Luca HF: Vitamin D: Historical overview. Vitamins and Hormones 2016; 100: 1–20.
35.
Carlberg C: Molecular approaches for optimizing vitamin D supplementation. Vitam Horm 2016; 100: 265–272.
36.
Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, Holick MF: The role of vitamin D in cancer prevention. Am J Public Health 2006; 96: 252–261.
37.
Helzlsouer KJ; VDPP Steering Committee: Overview of the cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol 2010; 172: 4–9.
38.
Ma Y, Johnson CS, Trump DL: Mechanistic insights of vitamin D anticancer effects. Vitam Horm 2016; 100: 395–431.
39.
Abe E, Miyaura C, Sakagami H, Takeda M, Konno K, Yamazaki T, Yoshiki S, Suda T: Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A 1981; 78: 4990–4994.
40.
Hadden MK: Hedgehog and vitamin D signaling pathways in development and disease. Vitam Horm 2016; 100: 232–254.
41.
Bikle DD: Vitamin D regulated keratinocyte differentiation. J Cell Biochem 2004; 92: 436–444.
42.
Dixon KM, Deo SS, Wong G, Slater M, Norman AW, Bishop JE, Posner GH, Ishizuka S, Halliday GM, Reeve VE, Mason RS: Skin cancer prevention: a possible role of 1,25dihydroxyvitamin D3 and its analogs. J Steroid Biochem Mol Biol 2005; 97: 137–143.
43.
Kim IM, Norris KC, Artaza JN: Vitamin D and cardiac differentiation. Vitam Horm 2016; 100: 299–320.
44.
Orme RP, Middleditch C, Waite L, Fricker RA: The role of vitamin D3 in the development and neuroprotection of midbrain dopamine neurons. Vitam Horm 2016; 100: 273–297.
45.
Xu Y, Sun Z: Molecular basis of klotho: from gene to function in aging. Endocr Rev 2015; 36: 174–193.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.